Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.

Morita A, Takahashi H, Ozawa K, Imafuku S, Nakama T, Takahashi K, Matsuyama T, Okubo Y, Kitamura S, Matsuda N, Zhao Y, Yokoyama M, Hayashi N, Terui T.

J Dermatol. 2019 Sep;46(9):745-751. doi: 10.1111/1346-8138.14997. Epub 2019 Jul 8.

2.

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.

Ann Intern Med. 2012 Dec 18;157(12):846-55. doi: 10.7326/0003-4819-157-12-201212180-00004.

PMID:
23247938
3.

Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.

Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.

J Drugs Dermatol. 2016 Oct 1;15(10):1192-1196.

PMID:
27741335
4.

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.

Br J Dermatol. 2019 Mar 27. doi: 10.1111/bjd.17919. [Epub ahead of print]

PMID:
30916379
5.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB.

N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.

6.

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.

Fotiadou C, Vakirlis E, Ioannides D.

Clin Cosmet Investig Dermatol. 2016 Oct 19;9:367-372. eCollection 2016. Review.

7.

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE.

J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2. doi: 10.1016/j.jaad.2018.05.040. Epub 2018 Jun 1.

PMID:
29860040
8.

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data.

Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A.

Dermatol Reports. 2018 Oct 1;10(2):7859. doi: 10.4081/dr.2018.7859. eCollection 2018 Oct 1.

9.

Interventions for hidradenitis suppurativa.

Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, Hood K, Burton T, Kerdel F, Garner SE, Piguet V.

Cochrane Database Syst Rev. 2015 Oct 7;(10):CD010081. doi: 10.1002/14651858.CD010081.pub2. Review.

10.

Adalimumab: A Review in Hidradenitis Suppurativa.

Kim ES, Garnock-Jones KP, Keam SJ.

Am J Clin Dermatol. 2016 Oct;17(5):545-552. Review.

PMID:
27665300
11.

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.

Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB.

J Eur Acad Dermatol Venereol. 2016 Jun;30(6):989-94. doi: 10.1111/jdv.13216. Epub 2015 Jul 22.

12.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.

Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.

Br J Dermatol. 2014 Dec;171(6):1434-42. doi: 10.1111/bjd.13270. Epub 2014 Nov 11.

PMID:
25040429
13.

Long-term successful adalimumab therapy in severe hidradenitis suppurativa.

Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.

Arch Dermatol. 2009 May;145(5):580-4. doi: 10.1001/archdermatol.2009.49.

PMID:
19451504
14.

Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.

Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N.

Clin Pharmacokinet. 2017 Sep;56(9):1091-1102. doi: 10.1007/s40262-016-0502-4.

PMID:
28066879
15.

A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.

Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D.

J Drugs Dermatol. 2012 May;11(5 Suppl):s15-20.

PMID:
22644772
16.

Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.

Gupta AK, Studholme C.

Skin Therapy Lett. 2016 Jul;21(4):1-4.

17.

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.

Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA.

Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6.

18.

Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.

Jiménez-Gallo D, de la Varga-Martínez R, Ossorio-García L, Collantes-Rodríguez C, Rodríguez C, Linares-Barrios M.

Cytokine. 2018 Mar;103:20-24. doi: 10.1016/j.cyto.2017.12.020. Epub 2017 Dec 28.

PMID:
29289722
19.

Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study

Kerdel FR, Azevedo FA, Kerdel Don C, Don FA, Fabbrocini G, Kerdel FA.

J Drugs Dermatol. 2019 Feb 1;18(2):170-176.

PMID:
30811140
20.

Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.

Zouboulis CC.

Expert Rev Clin Immunol. 2016 Oct;12(10):1015-26. doi: 10.1080/1744666X.2016.1221762. Epub 2016 Aug 29. Review.

PMID:
27531618

Supplemental Content

Support Center